Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Return on Equity (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Return on Equity for 10 consecutive years, with 0.58% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity fell 5.0% to 0.58% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.58%, a 5.0% decrease, with the full-year FY2025 number at 0.53%, down 3.0% from a year prior.
  • Return on Equity was 0.58% for Q4 2025 at Intellia Therapeutics, up from 0.61% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.25% in Q4 2021 to a low of 0.63% in Q2 2025.
  • A 5-year average of 0.44% and a median of 0.44% in 2022 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: rose 15bps in 2021, then decreased -21bps in 2022.
  • Intellia Therapeutics' Return on Equity stood at 0.25% in 2021, then plummeted by -76bps to 0.44% in 2022, then dropped by -2bps to 0.45% in 2023, then decreased by -19bps to 0.53% in 2024, then dropped by -9bps to 0.58% in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Return on Equity are 0.58% (Q4 2025), 0.61% (Q3 2025), and 0.63% (Q2 2025).